Ear acupuncture may offer some relief for women living with chronic migraine, according to new research presented at the Federation of European Neuroscience Societies Forum 2026.
The result is promising, although not yet conclusive. It points to a possible supportive therapy for a condition that can be relentless, costly, and deeply disruptive.
The treatment, known as auriculotherapy, uses the outer ear as a point of stimulation. In the trial, tiny semi-permanent needles were placed on selected ear points, then small mustard seeds were secured with high-adhesion medical tape to keep pressure on those points between sessions. The method is already used in some complementary medicine settings. What this study adds is a controlled scientific test in women with chronic migraine, using both symptom questionnaires and a brain oxygenation measure.
The study included 68 women treated by researchers at the University of Southern Santa Catarina in Brazil. All had been diagnosed with migraine for at least one year. All experienced migraine on 15 or more days each month. That detail matters. Chronic migraine is not simply a run of bad headaches. It is a neurological condition that can affect nearly every part of daily life, from work and sleep to parenting, exercise, social plans, memory, mood, and confidence.
Migraine attacks may bring moderate to severe head pain, often with nausea, sensitivity to light, sensitivity to sound, fatigue, dizziness, and difficulty concentrating. Some people also experience aura, which can include flashing lights, zigzag patterns, blind spots, tingling, or other neurological symptoms.
For those with chronic migraine, the problem is not only the attack itself. It is the constant planning around pain. The cancelled meetings. The quiet rooms. The fear of the next episode.
Women are affected far more often than men, roughly three times as often. Hormonal factors are thought to play a role, although migraine is driven by a wider mix of nervous system sensitivity, genetics, inflammation, sleep disruption, stress, vascular changes, and environmental triggers.
Many patients need several forms of care. Acute medicines can help stop attacks. Preventive treatments aim to reduce frequency. Lifestyle measures, physiotherapy, psychological support, neuromodulation devices, botulinum toxin injections, and newer migraine-specific drugs may also be part of care.
Still, many people do not get enough relief. Some cannot tolerate medicines. Some face limited access. Others improve only partly. That is why non-drug approaches continue to attract serious attention, especially when they can be tested with proper trial methods.
In this study, the researchers randomly assigned women to one of two groups. One group received auriculotherapy at ear points selected according to a migraine protocol. The other received a sham procedure. This comparison treatment looked similar, used needles and mustard seeds, but targeted ear points not considered specific to migraine. These included points linked to health benefits to areas such as the fingers, wrist, knee, arm, shoulder, lung, lower limbs, and spine.
Patients did not know which treatment they were receiving. The outcome assessors and the researchers analysing the statistics were also blinded to group allocation. The therapist delivering treatment knew which procedure was being used, which is difficult to avoid in a hands-on therapy. Each participant received eight sessions over eight weeks.
The researchers measured pain with the McGill Pain Questionnaire. They measured the effect of migraine on daily life using the Headache Impact Test, known as HIT-6. Assessments were carried out before treatment, immediately after the eight-week course, and again 30 days later.
The results showed improvement in both groups. In the auriculotherapy group, the average pain score fell from 50.5 before treatment to 44.7 immediately after treatment. After 30 days, it fell further to 41. That represented a reduction of about 11% at the end of treatment and 18% at follow-up.
The sham group improved too. Average pain scores fell from 50.2 before treatment to 44.3 immediately after the sessions, then to 43.9 at 30 days. Those figures represented reductions of around 12% and 13%. At the 30-day follow-up, both groups had significantly lower pain scores than before treatment.
The crucial point is this: the difference between the two groups was not statistically significant. The women improved over time, but the trial did not prove that migraine-specific auriculotherapy was better than the sham ear procedure.
That finding does not make the study unimportant. In fact, it makes it more useful. Without a sham group, the reduction in pain after auriculotherapy might have looked like strong evidence of a specific treatment effect. With the comparison group included, the picture becomes more careful.
Daily function followed a similar pattern. In the auriculotherapy group, the average HIT-6 score dropped from 66.1 before treatment to 60.7 immediately after treatment, then to 59.5 after 30 days. In the sham group, it fell from 65.8 to 59.2 after treatment, then to 59.3 at follow-up. Across both groups, this represented an improvement of roughly 8% to 10%.
For a patient, a change like that may still matter. A smaller burden can mean fewer hours in bed, less time away from work, fewer abandoned plans, or a slightly easier day after an attack. Migraine research must always balance statistical significance with lived experience. Yet clinical caution remains essential. A treatment can be interesting, plausible, and helpful to some patients without being proven superior in a trial.
The researchers also used haemoencephalography, or HEG, to assess brain physiology. This non-invasive method uses near-infrared spectroscopy to estimate blood flow and oxygenation in the brain. Small sensors are placed on the head. In this study, the focus was the prefrontal cortex, an area involved in attention, emotional regulation, decision-making, and pain processing.
Changes in average oxygenation levels were seen during the study. Differences between groups were also reported. However, the pattern over time was not clearly distinct between the active auriculotherapy group and the sham group. The finding suggests HEG may be useful in future migraine studies, especially as a way to monitor aspects of brain function. It does not yet show a clear biological signature for auriculotherapy.
The scientific interest in the ear is not random. The outer ear has nerve connections involving the vagus nerve, trigeminal nerve, and cervical nerves. These pathways are linked to pain regulation, autonomic activity, and inflammatory responses. Migraine itself involves neurovascular, autonomic, sensory, and neuroinflammatory changes. Researchers are exploring whether ear stimulation may influence the neuroimmune axis, the two-way communication system between the nervous and immune systems.
One possible explanation for the trial findings is that nonspecific ear stimulation may not be truly inactive. Even when points are not selected for migraine, needling and pressure on the ear may still stimulate nerve pathways involved in pain. Another explanation is the therapeutic context itself. Regular appointments, physical contact, expectation of benefit, relaxation, and careful monitoring can all affect how symptoms are experienced. Migraine also fluctuates naturally. Patients entering a trial during a severe period may improve over time regardless of treatment.
The study has strengths. It was randomised. It used a sham comparison. Patients were blinded. Assessors and statisticians were blinded. It used recognised migraine questionnaires. It also included an objective physiological measure. These features give the findings more weight than an uncontrolled report.
It also has limits. The trial was small, with 68 participants. It included only women. It focused on chronic migraine, not episodic migraine. Follow-up lasted 30 days after treatment, so longer-term effects remain unclear. The current findings cannot be assumed to apply to men, children, people with less frequent migraine, or patients with other headache disorders.
The practical message is balanced. Auriculotherapy may be a reasonable complementary option for some people with migraine, especially those looking for non-drug support alongside standard care. It should not replace prescribed medication, preventive therapy, emergency treatment, or medical review. People with sudden, severe, unusual, worsening, or new headache symptoms should seek urgent medical assessment.
The research gives migraine patients and clinicians something worth watching. It does not deliver a breakthrough. It does not prove a cure. It does show that women with chronic migraine reported less pain and less daily disruption after a structured course of ear stimulation. It also shows that the same kind of improvement can appear after sham stimulation.
That is the real news. Auriculotherapy remains promising, but inconclusive. Larger trials will need to test whether it has a specific effect, how long benefits last, which patients may respond best, and whether brain oxygenation changes can help explain what is happening.
For now, ear acupuncture sits in an interesting space: plausible, low-tech, low risk, patient-friendly, and not yet settled by the strong evidence. In migraine care, where many patients still need better options, that makes it worth trying and studying closely.
The post Ear Acupuncture May Ease Chronic Migraine Pain, Early Trial Finds first appeared on PP Health Malaysia.
